Nasdepi®: Revolutionizing Anaphylaxis Treatment
with Pain-Free Precision
Belhaven was founded in 2021 in Raleigh, North Carolina, with initial funding from local angels and support from the North Carolina Biotechnology Center. This funding enabled the initial formulation work to identify a lead formulation for Nasdepi® and confirmatory nonclinical studies in animal models.
In the second half of 2022, Belhaven successfully completed a pre-IND meeting with the US FDA confirming the development program requirements for Nasdepi®. Belhaven expanded its team to support the transition from research to clinical development and expansion of the product portfolio.
At Belhaven Biopharma, our focus extends beyond immediate solutions to pioneering a future where emergency medications are more affordable, effective, and user-friendly.
Our mission is to ensure that life saving medications are universally accessible and simpler to use through the development of dry powder nasal formulations.
Founded in 2021 in Raleigh, North Carolina, Belhaven Biopharma was created with the mission to bring life changing anaphylaxis treatment to patients worldwide. With support from the North Carolina Biotechnology Center and a team of visionary leaders, we are dedicated to enhancing emergency medical care.
Accelerated clinical development (bioequivalency)
Patented dry powder formulations
Multiple issued and pending patents
Easy to use, compact device
Product profile supports US market disruption and global expansion
Opportunity to meet military & government requirements for next generation products
At Belhaven Biopharma, our leadership team boasts extensive experience in the biopharma industry and combination product development. With backgrounds in top pharmaceutical companies and successful startups, our experts have a proven track record in drug development, quality assurance, and clinical operations. Our collective expertise enables us to navigate complex regulatory landscapes and bring innovative treatments like Nasdepi® to market. This depth of knowledge and dedication drives our mission to deliver life-saving allergy solutions with the highest standards of safety and efficacy.
Chief Executive Officer and Chairman of the Board
Experienced pharmaceutical executive and an entrepreneur with significant development success with companies such as Amgen, GSK, Valeant, and BioCryst.
Chief Financial Officer and Board Member
Leader in the Research Triangle Park startup community. Venture Partner with Duke Capital Partners.
Chief Operations Officer
Manufacturing and operations expert with significant experience in pharmaceutical development and international and government collaborations.
Head of Quality
Quality assurance executive specializing in the pharmaceutical and biotech sector with global and domestic experience.
Head of Regulatory
With 3 decades in the pharmaceutical industry, Lynn Gold oversees regulatory strategies at Belhaven, previously leading regulatory affairs at Impel Pharmaceuticals and Camargo Pharmaceutical Services.
Head of Clinical Operations
Overseas Belhaven’s clinical development portfolio, bringing 30 years of experience and having led global operations at Nestle Health Science and Aimmune Therapeutics.
Chief Executive Officer and Chairman of the Board
Chief Financial Officer and Board Member
Independent Board Member
Independent Board Member
Independent Board Member
Chairman
Copyright ©2025. All Rights Reserved.